Increased Rate of Phenocopies in All Age Groups in BRCA1/BRCA2 Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to BRCA2 Mutation Carriers

被引:12
|
作者
Evans, D. Gareth R. [1 ,2 ]
Ingham, Sarah L. [2 ,3 ]
Buchan, Iain [3 ]
Woodward, Emmar R. [4 ,5 ]
Byers, Helen [1 ]
Howell, Anthony [2 ]
Maher, Eamonn R. [4 ,5 ]
Newman, William G. [1 ]
Lalloo, Fiona [1 ]
机构
[1] Univ Manchester, Manchester Acad, St Marys Hosp, Hlth Sci Ctr,Dept Genet Med, Manchester M13 9WL, Lancs, England
[2] Univ S Manchester Hosp, Gene Prevent Ctr, Manchester, Lancs, England
[3] Univ Massachusetts, Ctr Hlth Informat, Inst Populat Hlth, Amherst, MA 01003 USA
[4] Univ Birmingham, Coll Med & Dent Sci, Ctr Rare Dis & Personalised Med, Sch Clin & Expt Med, Birmingham, W Midlands, England
[5] West Midlands Reg Genet Serv, Birmingham, W Midlands, England
关键词
GENOME-WIDE ASSOCIATION; FAMILY-SPECIFIC BRCA1; NEGATIVE WOMEN; POPULATION; PENETRANCE; NONCARRIERS; ALLELES; GENES;
D O I
10.1158/1055-9965.EPI-13-0316-T
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To establish, if among unaffected noncarrier relatives in a family with an established BRCA1/2 mutation, there is an increased risk of breast cancer. Methods: We identified 49 women with breast cancer who were first-degree relatives of a pathogenic mutation carrier among 807 BRCA1/2 families but who tested negative for the specific mutation. A prospective analysis of breast cancer from date of family ascertainment was performed for first-degree relatives of proven BRCA1/2 mutation carriers and compared with population-expected incidence rates. Results: Women who prospectively test negative for BRCA1/2 mutations showed excess risk of breast cancer to be confined to BRCA2 noncarriers with an observed: expected (O/E) ratio of 4.57 [95% confidence interval (CI) 2.50-7.67; P < 0.0001; O/E in BRCA1 noncarriers, 1.77]; this dropped to 2.01 for BRCA2 [relative risk (RR), 1.99; 95% CI, 0.54-5.10] from date of predictive test. Genotyping of 18 breast cancer susceptibility single-nucleotide polymorphisms (SNP) defined an RR of 1.31 for BRCA2 breast cancer phenocopies with a breast cancer diagnosis at age less than 60 years. Conclusion: Noncarriers remain at risk in the prospective follow-up of women who tested negative for BRCA1/2. Women testing negative in BRCA2 families may have increased risk of breast cancer compared with population levels, particularly with strong breast cancer history in close relatives. Any increased risk in BRCA1 families is likely to be insufficient to recommend additional interventions. Impact: Our work can help with counseling women from BRCA1/2 families who have tested negative, and could impact on how individual breast cancer risk is related back to these women. (C) 2013 AACR.
引用
收藏
页码:2269 / 2276
页数:8
相关论文
共 50 条
  • [41] Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    K Metcalfe
    S Gershman
    H T Lynch
    P Ghadirian
    N Tung
    C Kim-Sing
    O I Olopade
    S Domchek
    J McLennan
    A Eisen
    W D Foulkes
    B Rosen
    P Sun
    S A Narod
    British Journal of Cancer, 2011, 104 : 1384 - 1392
  • [42] Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    M Ahmed
    F Lalloo
    A Howell
    DG Evans
    Breast Cancer Research, 12
  • [43] Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
    Stjepanovic, Neda
    Lubinski, Jan
    Moller, Pal
    Armel, Susan Randall
    Foulkes, William D.
    Tung, Nadine
    Neuhausen, Susan L.
    Kotsopoulos, Joanne
    Sun, Ping
    Sun, Sophie
    Eisen, Andrea
    Narod, Steven A.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (02) : 515 - 523
  • [44] Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Ahmed, M.
    Lalloo, F.
    Howell, A.
    Evans, D. G.
    BREAST CANCER RESEARCH, 2010, 12 : S6 - S6
  • [45] Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Metcalfe, K.
    Gershman, S.
    Lynch, H. T.
    Ghadirian, P.
    Tung, N.
    Kim-Sing, C.
    Olopade, O. I.
    Domchek, S.
    McLennan, J.
    Eisen, A.
    Foulkes, W. D.
    Rosen, B.
    Sun, P.
    Narod, S. A.
    BRITISH JOURNAL OF CANCER, 2011, 104 (09) : 1384 - 1392
  • [46] Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers
    Bernholtz, Shiri
    Jakobson-Setton, Ariella
    Korach, Jacob
    Ben Baruch, Gilad
    Laitman, Yael
    Friedman, Eitan
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (03) : 981 - 985
  • [47] Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.
    Lee, Yeh Chen
    Milne, Roger L.
    Smith, Charmaine
    Picken, Sandra
    Camm, Stephanie
    McLachlan, Sue-Anne
    Friedlander, Michael
    Hopper, John L.
    Phillips, Kelly-Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers
    Shiri Bernholtz
    Ariella Jakobson-Setton
    Jacob Korach
    Gilad Ben Baruch
    Yael Laitman
    Eitan Friedman
    Breast Cancer Research and Treatment, 2012, 131 : 981 - 985
  • [49] Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers
    Milne, R. L.
    Antoniou, A. C.
    ANNALS OF ONCOLOGY, 2011, 22 : i11 - i17
  • [50] Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Hopper, JL
    Baron, JA
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) : 1010 - 1011